MyMD Pharmaceuticals Enrolls First Client in Phase 2 Medical Trial of MYMD-1 as a Treatment for Delaying Aging as well as Increasing Healthy And Balanced Lifespan

MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals (” MyMD” or “the Company”), a medical phase pharmaceutical firm dedicated to expanding healthy and balanced lifespan, today introduced that the initial client has been registered in the Company’s Phase 2 clinical trial of lead prospect MYMD-1, a dental immune regulator medication, as a therapy for postponing aging as well as broadening healthy life-span.

The key endpoint for the Phase 2 double-blind, placebo-controlled professional test is to attain a reduction in the circulating degrees of (TNF-α), growth death aspect receptor I (TNFRI) and also IL-6. TNF-α and also IL-6 are the proteins in the body that create swelling as well as help activate the process of aging. The second procedures of the test will be the security, tolerability, and pharmacokinetics in this population of patients.

” In a Stage 1 clinical test of MYMD-1, we demonstrated the medication’s statistically considerable efficacy in minimizing levels of TNF-α, a principal in triggering pathological aging, in the blood. The FDA has accepted TNF-α decrease as the key endpoint for our Stage 2 research, which our team believe positions us well for an effective Stage 2 end result,” stated Chris Chapman, M.D., Head Of State, Director as well as Chief Medical Policeman of MyMD. “The initiation of patient enrollment in this research developments our goal to slow down the aging procedure, avoid loss of muscle cells in aging, limitation frailty, and extend healthy and balanced lifespan.”

MyMD has actually mentioned that there are no FDA-approved medications for dealing with aging disorders and prolonging healthy life expectancy human beings, a market anticipated to be a minimum of $600 billion by 20251 according to a significant financial investment financial institution. TNF-α blockers are one of the most recommended medications by income, a global market of about $40 billion annually,2 and, according to Nature Aging journal,3 a downturn in maturing that would increase life expectancy by one year deserves $38 trillion and by one decade deserves $367 trillion.

Along with aging, MYMD-1’s unique activity in controling the body immune system as well as dealing with chronic inflammation is being created for the treatment of autoimmune illness, consisting of rheumatoid arthritis (RA), numerous sclerosis (MS), diabetes mellitus, and also inflammatory bowel illness.

” We plan to start composing methods for a Stage 2 pilot study of MYMD-1 for rheumatoid arthritis early this year,” Dr. Chapman noted. “The rising frequency of rheumatoid arthritis and other autoimmune and also inflammatory conditions are driving demand for TNF inhibitors like MYMD-1, and our team believe our by mouth administered drug with extremely low poisoning would be turbulent to the $60 billion market for RA if approved by the FDA for this sign.”

Rheumatoid arthritis influences around 40 million people around the world.4.

Regarding MYMD-1.

Initially created for autoimmune illness, MYMD-1’s key function is to slow down the aging procedure, stop sarcopenia and also frailty, and expand healthy and balanced lifespan. Because it can cross the blood-brain barrier as well as gain access to the central nerves (CNS), MYMD-1 is likewise positioned to be a feasible therapy for brain-related conditions. Its device of activity and efficiency in diseases consisting of numerous sclerosis (MS) as well as thyroiditis have been studied through cooperations with several scholastic organizations. MYMD-1 is likewise revealing pledge in pre-clinical studies as a possible therapy for blog post- COVID-19 difficulties and also as an anti-fibrotic as well as anti-proliferation healing.

MYMD-1 has revealed performance in pre-clinical research studies in regulating the immune system by performing as a selective prevention of growth necrosis factor-alpha (TNF-α), a chauffeur of chronic swelling. Unlike various other therapies, MYMD-1 has actually been received these pre-clinical research studies to precisely obstruct TNF-α when it ends up being overactivated in autoimmune conditions and also cytokine tornados, yet not block it from doing its normal task of being a very first -responder to any type of routine sort of moderate infection. MYMD-1’s simplicity of dental dosing is one more differentiator contrasted to currently readily available TNF-α blockers, every one of which need delivery by injection or infusion. No approved TNF inhibitor has ever before been dosed by mouth. Additionally, the drug is not immunosuppressive as well as has actually not been revealed to create the major adverse effects typical with conventional therapies that deal with inflammation.

Regarding MyMD Pharmaceuticals, Inc

. MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD), a professional stage pharmaceutical company committed to extending healthy and balanced life-span, is concentrated on creating two novel therapeutic platforms that treat the causes of illness rather than only attending to the symptoms. MYMD-1 is a drug system based upon a scientific phase little molecule that controls the immune system to regulate TNF-α, which drives persistent inflammation, as well as various other pro-inflammatory cell signaling cytokines. MYMD-1 is being created to postpone aging, rise longevity, and also deal with autoimmune diseases and also COVID-19- connected depression. The Business’s second drug platform, Supera-CBD, is being established to deal with chronic pain, dependency and also epilepsy. Supera-CBD is an unique synthetic derivative of cannabidiol (CBD) and is being created to deal with and also improve upon the rapidly expanding CBD market, that includes both FDA authorized drugs and CBD items not currently regulated as drugs. To learn more, see www.mymd.com.